RESTON, Va., June 26, 2007 (PRIME NEWSWIRE) -- TenthGate International, Inc., www.TenthGate.biz (Pink Sheets:TGTI), ("TenthGate"), an innovative medical holding company focusing on healthcare related life-changing technologies, announced the addition of the fourth and fifth technology licenses by their wholly owned subsidiary TenthGate Incorporated through Science & Technology Corporation at the University of New Mexico (STC.UNM) http://stc.unm.edu/ . The titles of the two new technology licenses acquired are:
"In vivo determination of melanocyte protection ability of sunscreens using reactive melanin radical formation as a relevant endpoint"
"Post Exposure Prophylaxis of Melanoma Causation"
The three previous related technologies licensed by TenthGate from STC.UNM include:
"Molecular imaging of melanoma"
"Molecular assay of the UVA protective efficacy of sunscreens"
"Detecting metastatic melanoma in sentinel lymph nodes by EPR (Electron Paramagnetic Resonance)"
Except for lung cancer in women, the incidence of melanoma is growing faster than any cancer in the United States. It has become one of the more common cancers among young adults.
Per Tim Novak, Chairman and Chief Executive Officer of TenthGate; "We continue to expand the scope of our intellectual properties surrounding this "life-changing" technology developed at the University of New Mexico School of Pharmacy by Dr. Graham Timmins. The focus is on understanding the causation factors of melanoma skin cancer, using Electron Paramagnetic Resonance (EPR) diagnostics at the melanin free radical level to help guide us to specific prevention strategies. Initial benefits will be directed at product retailers and manufacturers who can provide a more exact description of the protective effectiveness of their sunscreens and other cosmetic products, allowing consumers to make better informed decisions on responsible sun exposure protective measures. We have made application and are pending trademark approval for 'MPF' for 'Melanocyte Protective Factor', which will be used to quantitatively describe this new protective efficacy scale in a standardize fashion."
Description of TenthGate's EPR Technology Applications:
http://www.tenthgate.biz/mDP.html
About TenthGate
TenthGate International, Inc. is focused on the acquisition and development of life changing, health related technologies. The range of acquired technologies includes biotech/life sciences, diagnostic and unique medical devices. The Company has acquired several intellectual properties and licenses to date, two of which have obtained FDA approval. The company has obtained exclusive license for an emerging melanoma diagnostic and prevention technology utilizing Electron Paramagnetic Resonance (EPR) technology. TenthGate has identified several additional technologies for acquisition.
About STC.UNM
SCIENCE & TECHNOLOGY CORPORATION @ UNM ("STC.UNM") is a New Mexico nonprofit corporation with principle offices located in Albuquerque, NM. STC has been designated by the Regents of the University of New Mexico to administer all matters pertaining to protection, utilization and commercialization of the intellectual property developed at the University.
About Dr. Graham Timmins
http://hsc.unm.edu/pharmacy/faculty/Graham_Timmins.shtml
The TenthGate International, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3179
Safe Harbor Disclaimer
Except for the historical information contained herein, the matters discussed in this press release may include forward-looking statements or information. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of TenthGate International, Inc., and its affiliates, set forth herein and those preceded by or that include the words "believes," "expects," "given," "targets," "intends," "anticipates," "plans," "projects", "forecasts" or similar expressions, are forward-looking statements. Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties which could cause the Company's future results to differ materially from those anticipated. The Company assumes no obligation to update any of the information contained or referenced in this press release.